Tauns Laboratories (TSE:197A) Short-Term Debt: 円9,283 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:197A Tauns Laboratories Inc TSE:197A
15 GF Score
Price 円509.00
! 9 Warning Signs
View Full Analysis

What is Tauns Laboratories Short-Term Debt?

Tauns Laboratories TSE:197A +0.79% 15 Short-Term Debt is 円9,283 Mil as of Mar. 2026. GuruFocus rates TSE:197A with a GF Score™ of 15/100. The stock has 9 warning signs investors should review.

Tauns Laboratories's Short-Term Debt for the quarter that ended in Mar. 2026 was 円9,283 Mil.

Tauns Laboratories's quarterly Short-Term Debt increased from Sep. 2025 (円6,195 Mil) to Dec. 2025 (円9,283 Mil) but then stayed the same from Dec. 2025 (円9,283 Mil) to Mar. 2026 (円9,283 Mil).

Tauns Laboratories's annual Short-Term Debt increased from Jun. 2024 (円5,232 Mil) to Jun. 2025 (円5,615 Mil) and increased from Jun. 2025 (円5,615 Mil) to Jun. 2026 (円13,233 Mil).

Tauns Laboratories Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Tauns Laboratories Short-Term Debt Related Terms

Tauns Laboratories Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Tauns Laboratories's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tauns Laboratories Short-Term Debt Chart

Tauns Laboratories Annual Data
Trend Jun22 Jun23 Jun24 Jun25 Jun26
Short-Term Debt
1,932.00 4,232.00 5,232.00 5,614.92 13,232.77

Tauns Laboratories Quarterly Data
Jun22 Jun23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 5,614.92 6,195.22 9,283.17 9,283.17 13,232.77
TSE:197A
15GF Score
Tauns Laboratories Inc TSE:197A
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of 円9,283 Mil mean?
Tauns Laboratories (TSE:197A) has a Short-Term Debt of 円9,283 Mil as of Mar. 2026.
Is Tauns Laboratories' Short-Term Debt too high?
Tauns Laboratories' current Short-Term Debt is 円9,283 Mil. Overall, Tauns Laboratories has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Tauns Laboratories' Short-Term Debt compare to ISRG and BDX?
Tauns Laboratories' Short-Term Debt of 円9,283 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Tauns Laboratories's current Short-Term Debt is 円9,283 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tauns Laboratories stock overvalued right now?
Tauns Laboratories (TSE:197A) has a current Short-Term Debt of 円9,283 Mil. The current Short-Term Debt is 円9,283 Mil. Tauns Laboratories' overall GF Score™ is 15/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Tauns Laboratories (TSE:197A), the current Short-Term Debt is 円9,283 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tauns Laboratories Business Description

Address 761-1 Kamishima Izunokuni-shi, Shizuoka, JPN, 410-2325
Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.
15GF Score

Get the complete analysis for TSE:197A

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円509.00
Price